Andre Uddin
Stock Analyst at Research Capital
(4.70)
# 744
Out of 4,504 analysts
93
Total ratings
45.1%
Success rate
30.2%
Average return
Main Sectors:
Stocks Rated by Andre Uddin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: MDNA Medicenna Therapeutics Corp. | Maintained: Buy | $3.75 → $1.60 | $0.365 | +338.36% | 9 | Jun 29, 2026 | |
| TSX: EDT Spectral Medical Inc. | Maintained: Buy | $3.50 | $1.35 | +159.26% | 3 | May 31, 2026 | |
| TSXV: TLT Theralase Technologies Inc. | Maintained: Buy | $0.70 | $0.26 | +169.23% | 7 | May 25, 2026 | |
| TSXV: COV Covalon Technologies Ltd. | Maintained: Buy | $2.90 | $2.10 | +38.10% | 1 | May 22, 2026 | |
| NGEN NervGen Pharma | Maintained: Buy | $5.5 | $1.88 | +192.55% | 4 | Apr 10, 2026 | |
| TSX: SVA Sernova Biotherapeutics Inc | Maintained: Buy | $3.50 → $0.60 | $0.125 | n/a | 3 | Jun 19, 2025 | |
| TSX: GUD Knight Therapeutics Inc. | Upgraded: Buy | $6.50 → $7.50 | $9.80 | n/a | 11 | Mar 11, 2025 | |
| TSX: MDP Medexus Pharmaceuticals Inc. | Maintained: Buy | $5.50 → $5.90 | $5.19 | n/a | 9 | Mar 26, 2024 | |
| ABILF Ability Inc. | Maintained: Buy | $0.8 | $0.0001 | n/a | 1 | Aug 31, 2023 | |
| VPHIF Valeo Pharma Inc. | Maintained: Buy | $0.84 → $0.7 | $0.000001 | n/a | 4 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25.00 | $0.405 | n/a | 2 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $0.000001 | n/a | 1 | Dec 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1.60 → $2.27 | $0.015 | n/a | 3 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.65 → $1.50 | $17.13 | n/a | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.60 → $2.80 | $1.06 | n/a | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16.20 | $10.05 | n/a | 8 | Apr 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5.98 | $0.000001 | n/a | 9 | Feb 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.45 | n/a | 7 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $15.78 | n/a | 4 | Oct 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $14.25 | n/a | 1 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.75 | n/a | 1 | May 17, 2017 |
Medicenna Therapeutics Corp.
Jun 29, 2026
Maintained: Buy
Price Target: $3.75 → $1.60
Current: $0.365
Upside: +338.36%
Spectral Medical Inc.
May 31, 2026
Maintained: Buy
Price Target: $3.50
Current: $1.35
Upside: +159.26%
Theralase Technologies Inc.
May 25, 2026
Maintained: Buy
Price Target: $0.70
Current: $0.26
Upside: +169.23%
Covalon Technologies Ltd.
May 22, 2026
Maintained: Buy
Price Target: $2.90
Current: $2.10
Upside: +38.10%
NervGen Pharma
Apr 10, 2026
Maintained: Buy
Price Target: $5.5
Current: $1.88
Upside: +192.55%
Sernova Biotherapeutics Inc
Jun 19, 2025
Maintained: Buy
Price Target: $3.50 → $0.60
Current: $0.125
Upside: n/a
Knight Therapeutics Inc.
Mar 11, 2025
Upgraded: Buy
Price Target: $6.50 → $7.50
Current: $9.80
Upside: n/a
Medexus Pharmaceuticals Inc.
Mar 26, 2024
Maintained: Buy
Price Target: $5.50 → $5.90
Current: $5.19
Upside: n/a
Ability Inc.
Aug 31, 2023
Maintained: Buy
Price Target: $0.8
Current: $0.0001
Upside: n/a
Valeo Pharma Inc.
Jun 14, 2023
Maintained: Buy
Price Target: $0.84 → $0.7
Current: $0.000001
Upside: n/a
May 10, 2021
Maintained: Buy
Price Target: $25.00
Current: $0.405
Upside: n/a
Dec 11, 2020
Upgraded: Buy
Price Target: $8
Current: $0.000001
Upside: n/a
Oct 30, 2020
Maintained: Buy
Price Target: $1.60 → $2.27
Current: $0.015
Upside: n/a
May 8, 2020
Maintained: Buy
Price Target: $4.65 → $1.50
Current: $17.13
Upside: n/a
Apr 16, 2020
Maintained: Hold
Price Target: $7.60 → $2.80
Current: $1.06
Upside: n/a
Apr 7, 2020
Downgraded: Hold
Price Target: $16.20
Current: $10.05
Upside: n/a
Feb 26, 2020
Maintained: Buy
Price Target: $5.98
Current: $0.000001
Upside: n/a
Jan 13, 2020
Maintained: Buy
Price Target: n/a
Current: $2.45
Upside: n/a
Oct 31, 2019
Maintained: Buy
Price Target: $10
Current: $15.78
Upside: n/a
Nov 13, 2017
Rated: Buy
Price Target: n/a
Current: $14.25
Upside: n/a
May 17, 2017
Maintained: Buy
Price Target: $15
Current: $1.75
Upside: n/a